© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Syndax Pharmaceuticals, Inc. (SNDX) stock declined over -0.34%, trading at $17.62 on NASDAQ, down from the previous close of $17.68. The stock opened at $17.64, fluctuating between $17.36 and $17.96 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | 17.65 | 17.95 | 17.37 | 17.62 | 5.18M |
| Sep 17, 2026 | 17.53 | 18.05 | 17.37 | 17.68 | 2.58M |
| Sep 16, 2026 | 18.08 | 18.11 | 17.25 | 17.28 | 2.33M |
| Sep 15, 2026 | 18.19 | 18.19 | 17.71 | 18.09 | 1.13M |
| Sep 14, 2026 | 18.30 | 18.68 | 18.24 | 18.35 | 1.14M |
| Sep 11, 2026 | 19.01 | 19.02 | 18.02 | 18.18 | 1.22M |
| Sep 10, 2026 | 19.67 | 19.69 | 18.40 | 18.82 | 1.65M |
| Sep 09, 2026 | 19.82 | 20.20 | 19.69 | 19.84 | 1.24M |
| Sep 08, 2026 | 20.19 | 20.48 | 19.90 | 19.94 | 1.2M |
| Sep 04, 2026 | 20.46 | 21.00 | 20.46 | 20.56 | 1.36M |
| Sep 03, 2026 | 20.85 | 20.99 | 20.54 | 20.68 | 1.92M |
| Sep 02, 2026 | 20.23 | 21.00 | 19.97 | 20.78 | 2.02M |
| Sep 01, 2026 | 19.29 | 20.15 | 19.09 | 20.10 | 1.41M |
| Aug 31, 2026 | 19.44 | 19.46 | 19.00 | 19.29 | 1.4M |
| Aug 28, 2026 | 19.98 | 20.05 | 19.47 | 19.54 | 1.04M |
| Aug 27, 2026 | 20.01 | 20.23 | 19.70 | 20.16 | 652.35K |
| Aug 26, 2026 | 19.92 | 20.22 | 19.60 | 20.09 | 789.66K |
| Aug 25, 2026 | 19.73 | 20.40 | 19.70 | 19.92 | 974.97K |
| Aug 24, 2026 | 19.70 | 19.87 | 19.17 | 19.57 | 1.44M |
| Aug 21, 2026 | 19.93 | 20.28 | 19.25 | 19.65 | 1.7M |
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
| Employees | 298 |
| Beta | 0.37 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | -1% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |